Recruiting OBSERVATIONAL NCT06676527

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

Sponsor: Jinling Hospital, China

Conditions Antineoplastic Agents Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Renal Cell Cancer Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Interventions Follow-up study of the treated cohort

Updated 2 times since 2024 Last updated: Dec 4, 2025 Started: Sep 1, 2024 Primary completion: Sep 1, 2026 Completion: Sep 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Antineoplastic Agents and Carcinoma and is currently actively recruiting participants. Jinling Hospital, China leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Recruiting
Dec 2024 — Jan 2026 [monthly]

Recruiting

First recorded

Sep 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jinling Hospital, China

Data source: Jinling Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China